RMD Quote, Financials, Valuation and Earnings

Baxter International, Inc. has a net margin of 27.59% compared to ResMed, Inc.'s net margin of -34.8%. ResMed, Inc.'s return on equity of 25.44% beat Baxter International, Inc.'s return on equity of -12.97%.

ResMed, Inc. has a consensus price target of $297.47, signalling upside risk potential of 14.89%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.63 which suggests that it could fall by -1.08%. Given that ResMed, Inc. has higher upside potential than Baxter International, Inc., analysts believe ResMed, Inc. is more attractive than Baxter International, Inc..

ResMed, Inc. has a beta of 0.869, which suggesting that the stock is 13.099% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.747%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.9%. Baxter International, Inc. offers a yield of 2.38% to investors and pays a quarterly dividend of $0.01 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

ResMed, Inc. quarterly revenues are $1.4B, which are smaller than Baxter International, Inc. quarterly revenues of $3B. ResMed, Inc.'s net income of $392.6M is higher than Baxter International, Inc.'s net income of -$1B. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.59x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.04x versus 1.00x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 27.59% compared to ResMed, Inc.'s net margin of 12.68%. ResMed, Inc.'s return on equity of 25.44% beat Boston Scientific Corp.'s return on equity of 12.55%.

ResMed, Inc. has a consensus price target of $297.47, signalling upside risk potential of 14.89%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.78 which suggests that it could grow by 37.36%. Given that Boston Scientific Corp. has higher upside potential than ResMed, Inc., analysts believe Boston Scientific Corp. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.869, which suggesting that the stock is 13.099% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.9%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.4B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. ResMed, Inc.'s net income of $392.6M is lower than Boston Scientific Corp.'s net income of $670M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.59x while Boston Scientific Corp.'s PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.04x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 27.59% compared to ResMed, Inc.'s net margin of 15.47%. ResMed, Inc.'s return on equity of 25.44% beat Globus Medical, Inc.'s return on equity of 10.08%.

ResMed, Inc. has a consensus price target of $297.47, signalling upside risk potential of 14.89%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 18.88%. Given that Globus Medical, Inc. has higher upside potential than ResMed, Inc., analysts believe Globus Medical, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.869, which suggesting that the stock is 13.099% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.9%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.4B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. ResMed, Inc.'s net income of $392.6M is higher than Globus Medical, Inc.'s net income of $119M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.59x while Globus Medical, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.04x versus 4.49x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 27.59% compared to ResMed, Inc.'s net margin of 11.84%. ResMed, Inc.'s return on equity of 25.44% beat Stryker Corp.'s return on equity of 15.17%.

ResMed, Inc. has a consensus price target of $297.47, signalling upside risk potential of 14.89%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 12.48%. Given that ResMed, Inc. has higher upside potential than Stryker Corp., analysts believe ResMed, Inc. is more attractive than Stryker Corp..

ResMed, Inc. has a beta of 0.869, which suggesting that the stock is 13.099% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.9%. Stryker Corp. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.88 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.4B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. ResMed, Inc.'s net income of $392.6M is lower than Stryker Corp.'s net income of $849M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.59x while Stryker Corp.'s PE ratio is 44.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 7.04x versus 5.81x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.